Innovent Biologics Receives Approval for New Lung Cancer Treatment

Innovent Biologics Makes Breakthrough in Precision Therapy for Lung Cancer Patients

SAN FRANCISCO and SUZHOU, China, Dec. 20, 2024 – Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801) has received approval from China’s National Medical Products Administration (NMPA) for their new drug DOVBLERON® (taletrectinib adipate capsule), a next-generation ROS1 tyrosine kinase inhibitor (TKI), aimed at the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who have previously been treated with ROS1 TKIs. This marks a significant milestone for Innovent and a breakthrough in precision therapy.

This approval makes DOVBLERON® the 13th addition to Innovent’s commercial portfolio, further solidifying their position as a world-class biopharmaceutical company that specializes in developing, manufacturing, and commercializing high-quality medicines for the treatment of various diseases, including oncology, cardiovascular and metabolic, autoimmune, ophthalmology, and more.

DOVBLERON® is expected to provide new hope for lung cancer patients, particularly those who have not responded to previous treatments. As a next-generation TKI, it represents a cutting-edge approach to treating NSCLC and underscores Innovent’s commitment to advancing innovative therapies that can benefit a broad range of patients.

Effects on Individuals

For individuals diagnosed with ROS1-positive NSCLC, the approval of DOVBLERON® offers a new treatment option that may improve outcomes and quality of life. Patients who have not responded to previous therapies now have access to a precision medicine that targets the specific genetic mutation driving their cancer, potentially leading to better responses and prolonged survival.

Effects on the World

The approval of DOVBLERON® represents a significant advancement in the field of precision medicine and personalized cancer treatment. By expanding the available options for patients with ROS1-positive NSCLC, this new drug has the potential to make a positive impact on the global fight against lung cancer and set a new standard for targeted therapies in oncology.

Conclusion

The approval of DOVBLERON® by China’s NMPA is a testament to Innovent’s dedication to developing innovative medicines that can make a meaningful difference in the lives of patients. This new precision therapy represents a beacon of hope for those affected by ROS1-positive NSCLC, offering a promising treatment option where others have fallen short. With this milestone, Innovent has demonstrated their commitment to advancing the field of oncology and bringing new solutions to the forefront of cancer treatment.